The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining ...

Duke University has been studying a new treatment for prostate cancer patients. Doctors say it is helping them live longer.

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

Castration-resistant prostate cancer (CRPC) remains incurable, due to resistance to therapies including the new generation of androgen receptor pathway inhibitors (ARPIs) such as enzalutamide.

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Scott T. Tagawa discussing ProstACT Global, a phase 3 study of 177 Lu-rosptamab + standard of care ...

prostate cancer therapy Xtandi (enzalutamide), and Inlyta (axitinib) for kidney cancer. That shift could protect the company from some of the price-cutting measures in the Inflation Reduction Act ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...

treated with XTANDI™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen depri NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an ...